MTFB - Motif Bio plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7600
+0.0101 (+1.35%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.7499
Open0.7100
Bid0.7500 x 4000
Ask0.8299 x 1400
Day's Range0.7100 - 0.8358
52 Week Range0.7000 - 11.5000
Volume544,437
Avg. Volume144,546
Market Cap12.353M
Beta (3Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-1.4400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Motif Bio Presents New Iclaprim Data at ASM Microbe 2019

    Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new iclaprim data were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting held in San Francisco, CA, USA, June 20-24, 2019. Data presented included an analysis of the pharmacokinetics of the iclaprim fixed dose used in the REVIVE Phase 3 trials in acute bacterial skin and skin structure infections (ABSSSI) compared to the weight-based dose used in the earlier ASSIST trials with iclaprim for complicated skin and skin structure infections (cSSSI) (Population Pharmacokinetic (PK) Analysis of the Fixed Dose of Iclaprim in the Phase 3 REVIVE Studies for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).  The analysis showed that two efficacy parameters (AUC/MIC and T MIC2) were improved with the fixed two-hour 80mg dose by 54% and 67%, respectively.  Cmax was improved by 7% with the fixed dose compared to the 30-minute weight-based dose.

  • PR Newswire18 days ago

    Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

    The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...

  • GlobeNewswire19 days ago

    Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes

    Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received the official minutes of the Type A meeting the Company held with the U.S. Food & Drug Administration (FDA or Agency) on May 3, 2019, to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for iclaprim, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company has been encouraged by the FDA to put forth a proposal for a future study and to submit it for review. The Company plans to request a meeting with the Agency to discuss the design of the study, including the appropriate patient population to be evaluated.

  • GlobeNewswire25 days ago

    Result of Annual General Meeting

    NEW YORK, May 31, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the.

  • GlobeNewswirelast month

    Motif Bio plc AGM Statement

    NEW YORK, May 22, 2019 -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the.

  • GlobeNewswirelast month

    Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology

    NEW YORK, May 22, 2019 -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the.

  • GlobeNewswirelast month

    Motif Bio to Present Iclaprim Data at ASM Microbe 2019

    NEW YORK, May 21, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three.

  • GlobeNewswire2 months ago

    Motif Bio meeting with U.S. FDA held as planned

    NEW YORK, May 03, 2019 -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company.

  • GlobeNewswire2 months ago

    Motif Bio Signs Agreement with Lamellar Biomedical

    NEW YORK, May 01, 2019 -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the.

  • GlobeNewswire2 months ago

    Motif Bio plc: Notice of Annual General Meeting

    NEW YORK, April 26, 2019 -- Motif Bio plc ("Motif Bio" or the "Company") (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel.

  • GlobeNewswire2 months ago

    Motif Bio Announces Appointment of Andrew Powell to Board of Directors

    Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately. Mr. Powell has served as General Counsel at several biotechnology firms, including CollaGenex Pharmaceuticals, ImClone Systems, Cornerstone Therapeutics, InterMune and, most recently, Medivation.

  • Benzinga2 months ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • GlobeNewswire2 months ago

    Motif Bio Presents New Iclaprim Data at ECCMID 2019

    NEW YORK, April 16, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that new.

  • GlobeNewswire2 months ago

    Motif Bio Reports Fiscal Year 2018 Results

    NEW YORK, April 15, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial.

  • PR Newswire2 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire3 months ago

    Motif Bio to Present Iclaprim Data at ECCMID 2019

    NEW YORK, April 04, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four.

  • Benzinga3 months ago

    The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 19) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • GlobeNewswire3 months ago

    Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim

    NEW YORK, March 20, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the.

  • GlobeNewswire3 months ago

    Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board

    Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and is stepping down from the Board of Directors, effective immediately, to focus on other business commitments. Bruce Williams, a long-standing Board member, has been appointed Interim Chairman. Mr. Morgan has agreed to remain available to the Company in the coming months on an as needed basis to ensure a smooth transition.

  • Zacks Small Cap Research4 months ago

    MTFB: FDA Issues CRL for Iclaprim…

    By David Bautz, PhD NASDAQ:MTFB READ THE FULL MTFB RESEARCH REPORT Business Update CRL for Iclaprim On February 14, 2019, Motif Bio Plc (NASDAQ:MTFB) announced that the U.S. FDA issued a complete response ...

  • GlobeNewswire4 months ago

    Motif Bio Conference Call and Webcast

    NEW YORK, Feb. 19, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the.

  • GlobeNewswire4 months ago

    Motif BioSciences Enters into Amendment Agreement with Hercules Capital

    Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif BioSciences Inc. (a wholly owned subsidiary) has entered into an amendment agreement with its lender Hercules Capital, Inc (HTGC) (“Hercules”) in relation to the loan agreement as notified on 15 November 2017. Pursuant to the amendment, Motif BioSciences Inc. will make an immediate early repayment of $7 million and will make a further repayment of $0.5 million on the earlier of 90 days, being 18 May 2019, or receipt of funds from an equity raise of $2 million or greater. There will be a three-month interest-only period on the remaining loan, and Hercules has waived any applicable prepayment charges.  As a result, future interest and amortisation payments will be substantially lower than before.

  • GlobeNewswire4 months ago

    Motif Bio Receives Complete Response Letter from the FDA

    Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The CRL states that the FDA cannot approve the NDA in its present form and indicates that additional data are needed to further evaluate the risk for liver toxicity before the NDA may be approved. Motif Bio plans to request a meeting with the FDA as soon as possible to discuss potential options to address the deficiencies.

  • PR Newswire5 months ago

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • GlobeNewswire8 months ago

    Motif Bio to participate at upcoming Jefferies London Healthcare Conference

    NEW YORK, Oct. 31, 2018 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the.